SGLT2 Inhibition by Enavogliflozin Significantly Reduces Aβ Pathology and Restores Cognitive Function via Upregulation of Microglial AMPK Signaling in 5XFAD Mouse Model of Alzheimer's Disease
Aging Cell · 2025
DOI: 10.1111/acel.70101 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging Cell, 2025. Verfasst von Jihui Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Alzheimer Disease, Sodium-Glucose Transporter 2 Inhibitors, Microglia, Cognition. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Dementia Research Center, Daewoong Pharmaceutical Company.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline. Metabolic dysfunctions, particularly type 2 diabetes mellitus (T2DM), have been implicated in AD pathogenesis, highlighting the potential for novel therapeutic approaches targeting shared underlying mechanisms. Here, we investigate sodium‐glucose cotransporter 2 (SGLT2) inhibition as a therapeutic strategy for AD using Enavogliflozin, a potent SGLT2 inhibitor, in the 5XFAD mouse model. Five‐month‐old 5XFAD mice were treated with Enavogliflozin (0.1 or 1 mg/kg) or vehicle for 8 weeks. The higher dose significantly improved cognitive performance in Y‐maze and Morris Water Maze tests, which correlated with enhanced synaptic plasticity and increased acetylcholine levels. Moreover, Enavogliflozin treatment reduced Aβ pathology and plaque burden, particularly affecting larger plaques. Mechanistically, SGLT2 inhibition attenuated neuroinflammation by suppressing NF‐κB signaling and proinflammatory cytokine production while promoting microglial recruitment to plaques. In vitro and ex vivo analyses further revealed that Enavogliflozin enhances microglial phagocytic capacity via AMPK‐mediated mitochondrial biogenesis and function. These findings highlight the multifaceted neuroprotective effects of SGLT2 inhibition in AD, demonstrating its potential to mitigate pathology and improve cognitive function. By uncovering its impact on neuroinflammation and microglial function, this study establishes SGLT2 inhibition as a promising therapeutic avenue for AD and other neurodegenerative disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea.
- Convergence Dementia Research Center, College of Medicine, Seoul National University, Seoul, Republic of Korea.
- Life Science Institute, Daewoong Pharmaceutical, Yongin, Republic of Korea.
ORCID-Profile: Inhee Mook-Jung
Förderung
- Korea Dementia Research Center
- Daewoong Pharmaceutical Company
Zitieren
APA
Han, J., Song, J., Jung, E. S., Choi, J. W., Ji, H. Y., & Mook-Jung, I. (2025). SGLT2 Inhibition by Enavogliflozin Significantly Reduces Aβ Pathology and Restores Cognitive Function via Upregulation of Microglial AMPK Signaling in 5XFAD Mouse Model of Alzheimer's Disease. Aging Cell. https://doi.org/10.1111/acel.70101
Vancouver
Han J, Song J, Jung ES, Choi JW, Ji HY, Mook-Jung I. SGLT2 Inhibition by Enavogliflozin Significantly Reduces Aβ Pathology and Restores Cognitive Function via Upregulation of Microglial AMPK Signaling in 5XFAD Mouse Model of Alzheimer's Disease. Aging Cell. 2025. doi:10.1111/acel.70101
BibTeX
@article{Han2025,
author = {Han, Jihui and Song, Jaehoon and Jung, Eun Sun and Choi, Ji Won and Ji, Hye Young and Mook-Jung, Inhee},
title = {SGLT2 Inhibition by Enavogliflozin Significantly Reduces Aβ Pathology and Restores Cognitive Function via Upregulation of Microglial AMPK Signaling in 5XFAD Mouse Model of Alzheimer's Disease},
journal = {Aging Cell},
year = {2025},
doi = {10.1111/acel.70101}
}
EUVIMED